)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Editas Medicine (EDIT) investor relations material
Editas Medicine Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Focus shifted to in vivo gene editing, nominating EDIT-401 for hyperlipidemia as lead candidate, with IND/CTA submission planned by mid-2026 and initial human data by end of 2026.
Lead in vivo candidate EDIT-401 demonstrated >90% LDL-C reduction in non-human primates, supporting its potential as a best-in-class, one-time therapy.
Discontinued ex vivo reni-cel program for sickle cell and beta thalassemia in December 2024, resulting in a 65% workforce reduction and major restructuring.
Collaboration with BMS extended to November 2026, with milestone revenue recognized in Q3 2025; Vertex license continues to provide non-dilutive capital.
Cash runway extended into Q3 2027, supporting EDIT-401 development beyond initial human data.
Financial highlights
Revenue for Q3 2025 was $7.5M, up from $0.1M in Q3 2024, driven by a BMS milestone; nine-month revenue was $15.8M, up from $1.7M year-over-year.
Net loss for Q3 2025 was $25.1M ($0.28/share), a 60% improvement from $62.1M ($0.75/share) in Q3 2024; nine-month net loss was $154.4M, down from $191.7M year-over-year.
Operating expenses for Q3 2025 were $32.1M, down 51% year-over-year; R&D expenses decreased to $19.8M and G&A expenses to $12.3M, reflecting program discontinuation and workforce reductions.
Cash, cash equivalents, and marketable securities totaled $165.6M as of September 30, 2025, down from $269.9M at December 31, 2024.
Restructuring and impairment charges totaled $66.9M for the nine months ended September 30, 2025.
Outlook and guidance
Existing cash and equivalents expected to fund operations into Q3 2027, supported by ATM facility proceeds and license payments.
IND/CTA filing for EDIT-401 planned by mid-2026; initial human proof-of-concept data expected by year-end 2026.
Expenses anticipated to increase as EDIT-401 advances to clinical stage and preclinical pipeline expands.
No profitability expected in 2025 or the foreseeable future.
Significance of 10-40% LDLR editing for EDIT-401?
Future cost structure post reni-cel program
What are the funding plans beyond Q3 2027?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Editas Medicine earnings date
Q4 20255 Mar, 2026
Next Editas Medicine earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage